DUBLIN--(BUSINESS WIRE)--The "Human Growth Hormone Market by Application Route of Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
The global human growth hormone market was valued at $2,840.70 million in 2018 and is expected to reach $5,563.60 million by 2026, registering a CAGR of 8.6% from 2019 to 2026.
Human growth hormone is a protein made by the pituitary gland and is secreted into the bloodstream to other parts of the body. Its production is regulated by an intricate set of hormones produced in the hypothalamus gland, intestinal tract, and pancreas. Further, these hormones act on several tissues throughout the body. In adolescents, it stimulates the growth of bone and cartilage. Whereas in adults, it boosts protein production, promotes the utilization of fat, interferes with the action of insulin, and raises blood sugar levels. GH also raises levels of insulin-like growth factor1.
Surge in awareness regarding the effectiveness of growth hormones and increase in prevalence of chronic diseases including growth retardation and pituitary dysfunctions and surge in compliance for growth hormone formulations are the major factors that drive the growth of the global human growth hormone market. However, the side effects associated with its vigorous usage such as muscle pain, joint pain, and fluid retention and high cost of the treatment hampers the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years. Furthermore, rise in disposable income and surge in healthcare expenditure in developing economies is anticipated to create lucrative growth opportunities for the market.
The human growth hormone market can be segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, and small for gestational age, and others . By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. On the basis of distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
Key Finding of The Human Growth Hormone Market:
- By application, the Turner Syndrome segment dominated the market in 2018 and is anticipated to continue the same during the forecast period.
- By region, North America was the major shareholder and accounted for the highest share of 48% in 2018.
- By route of administration, the subcutaneous segment is expected to grow at a CAGR of 9.1% during the forecast period.
- By distribution channel, the hospital pharmacy segment dominated the human growth hormone market in 2018 and is anticipated to maintain its dominance during the forecast period.
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Porter'S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
22.214.171.124. Increase In Usage Of Growth Hormone To Control Aging
126.96.36.199. Surge In Disorders Related To Growth Hormone Deficiency
188.8.131.52. Side Effects Associated With The Treatment
184.108.40.206. Rise In Awareness Towards Usage Of Human Growth In Developing Economies
Chapter 4: Human Growth Hormone Market, By Application
4.1.1. Market Size And Forecast, By Application
4.2. Growth Hormone Deficiency
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Prader-Willi Syndrome
4.4. Turner Syndrome
4.5. Small For Gestational Age (Sga)
Chapter 5: Human Growth Hormone Market, By Route Of Administration
Chapter 6: Human Growth Hormone Market, Distribution Channel
6.2. Hospital Pharmacy
6.3. Retail Pharmacy
6.4. Online Pharmacy
Chapter 7: Human Growth Hormone Market, By Region
7.2. North America
Chapter 8: Company Profiles
8.1. Novo Nordisk
8.2. Merck & Co.
8.3. Eli Lilly And Company.
8.4. Pfizer Inc.
8.5. Teva Pharmaceutical Industries.
8.6. Novartis Ag
8.7. Anhui Anke Biotechnology (Group) Co., Ltd.
8.10. Ferring Bv
For more information about this report visit https://www.researchandmarkets.com/r/v4ocsv